Testing Coartem baby tablets for malaria in infants weighing 2 to 5 kg
Part of Infections clinical trials.
This study tests a special dispersible tablet for infants with uncomplicated malaria. It aims to see if the medicine is safe and works well for babies weighing 2 to 5 kg.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be between 2 and 5 kg (about 4.4 to 11 pounds).
- Your baby must have a confirmed case of mild malaria caused by the Plasmodium parasite.
- Your baby must be able to take Coartem® Baby tablets as prescribed.
- Your baby must not have severe malaria or any heart rhythm problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how artesunate works in infants under 2 years old being treated for severe malaria. It aims to learn more about the medicine to help improve treatment for babies.
This study follows people who were pregnant while receiving IV artesunate to better understand the treatment’s safety for both the mother and the baby. It does not test a new treatment—it collects safety information from real-world care.
This study tests how well a malaria treatment plan works for people with P. vivax malaria who don’t have another malaria type at the same time. It aims to see whether adding or using different medicines (ACT vs chloroquine with tafenoquine) helps clear infection and prevent return of disease.
This study aims to find the best way to treat or prevent malaria in children with HIV. It may also help children without HIV who live in areas where malaria is common.
This trial tests whether adding a cancer drug called imatinib to standard malaria treatment works better and is safe. Researchers will enroll adults and children with uncomplicated malaria caused by P. falciparum parasites and monitor them in the hospital for 2–3 days.
This trial studies how well and how safely different anti-malaria medicines work for people who have uncomplicated malaria caused by Plasmodium falciparum. You may be eligible if you have a confirmed infection with a certain parasite level and do not have signs of severe disease or major health conditions.
Hear when a new Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.